Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Watanabe, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Medical Treatment of West Syndrome in Japan

Kazuyoshi Watanabe, MD

Department of Pediatrics, Nagoya University School of Medicine, Nagoya, Japan

Although corticotropin (ACTH) is still the most effective drug for the treatment of West syndrome, a variety of other treatment modalities have been tried because of corticotropin's frequent and sometimes serious side effects. A recent survey on the treatment of this devastating disorder by Japanese child neurologists disclosed different therapeutic approaches from those taken by American or European child neurologists. Most Japanese child neurologists use vitamin B6 as the first agent and corticotropin as the third or second drug. Moreover, the dosage of corticotropin used by them is considerably smaller. Therefore, the current status of medical treatment of West syndrome is reviewed, especially comparing Japan with other countries. (J Child Neurol 1995;10:143-147).

Journal of Child Neurology, Vol. 10, No. 2, 143-147 (1995)
DOI: 10.1177/088307389501000217
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Child NeurolHome page
T. Tsuji, A. Okumura, H. Ozawa, M. Ito, and K. Watanabe
Current Treatment of West Syndrome in Japan
J Child Neurol, May 1, 2007; 22(5): 560 - 564.
[Abstract] [PDF]

Home page
 Arch. Dis. Child.Home page
H-S Wang, M-F Kuo, M-L Chou, P-C Hung, K-L Lin, M-Y Hsieh, and M-Y Chang
Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy
Arch. Dis. Child., May 1, 2005; 90(5): 512 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
R Gupta and R Appleton
Corticosteroids in the management of the paediatric epilepsies
Arch. Dis. Child., April 1, 2005; 90(4): 379 - 384.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Ito, T. Miyajima, T. Fujii, and T. Okuno
Subdural hematoma during low-dose ACTH therapy in patients with West syndrome
Neurology, June 27, 2000; 54(12): 2346 - 2347.
[Full Text] [PDF]

Home page
 J Child NeurolHome page
M. Ito, T. Seki, and Y. Takuma
Current Therapy for West Syndrome in Japan
J Child Neurol, June 1, 2000; 15(6): 424 - 428.
[Abstract] [PDF]